Malgorzata Tuxen - Concepedia

Author

Malgorzata Tuxen

Also Known As

M K Tuxen, M. K. TUXEN, M. K. Tuxen, M. Kolyszko Tuxen, M. Tuxen, M.K. TUXEN, M.K. Tuxen, Malgorzata K Tuxen, Malgorzata K. Tuxen, Malgorzata Tuxen

Publications

2.6K

Citations

H-Index

Concepts

All Affiliations

Herlev Hospital University of Copenhagen Rigshospitalet Copenhagen University Hospital St. Vincent's University Hospital

About

Malgorzata Tuxen is an author at Herlev Hospital specializing in oncology, medicine, and obstetrics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	10	11	618
2	Public Health	2	2	51
3	Engineering	1	1	18
4	Health Sciences	1	1	38
5	Nursing	1	1	18

Malgorzata Tuxen

Publications

Citations

H-Index

Page 1

	Year	Citations
Exploratory Phase III Study of Paclitaxel and Cisplatin Versus Paclitaxel and Carboplatin in Advanced Ovarian Cancer Jan P. Neijt, Svend Aage Engelholm, Malgorzata Tuxen, Journal of Clinical Oncology	2000	441
CA125 in ovarian cancer: European Group on Tumor Markers guidelines for clinical use Michael J. Duffy, J. M. G. Bonfrer, J Kulpa, International Journal of Gynecological Cancer	2005	297
Defining progression of ovarian carcinoma during follow-up according to CA 125: A North Thames Ovary Group study G.J.S. Rustin, Ann E. Nelstrop, Malgorzata Tuxen, Annals of Oncology Tumoral PathologyCa 125MedicineGynecologyOvarian Carcinoma	1996	284
Clinical Use of Cancer Biomarkers in Epithelial Ovarian Cancer György Sölétormos, Michael J. Duffy, Suher Othman Abu Hassan, International Journal of Gynecological Cancer	2015	258
Advanced epithelial ovarian cancer: 1998 consensus statements. Jonathan S. Berek, K. Bertelsen, Andreas du Bois, Annals of Oncology	1999	124
Effect of adding gefitinib to neoadjuvant chemotherapy in estrogen receptor negative early breast cancer in a randomized phase II trial Mogens Bernsdorf, Christian Ingvar, Leif Jørgensen, Breast Cancer Research and Treatment Breast OncologyOncologyMedicineGynecologyBreast Cancer	2011	79
Serum tumour marker CA 125 in monitoring of ovarian cancer during first-line chemotherapy Malgorzata Tuxen, György Sölétormos, P Dombernowsky British Journal of Cancer	2001	67
Adjuvant Cyclophosphamide and Docetaxel With or Without Epirubicin for Early<i>TOP2A</i>-Normal Breast Cancer: DBCG 07-READ, an Open-Label, Phase III, Randomized Trial Bent Ejlertsen, Malgorzata Tuxen, Erik Jakobsen, Journal of Clinical Oncology	2017	65
Assessment of Biological Variation and Analytical Imprecision of CA 125, CEA, and TPA in Relation to Monitoring of Ovarian Cancer Malgorzata Tuxen, György Sölétormos, Per Hyltoft Petersen, Gynecologic Oncology RadiologyCa 125Cancer DetectionMedicineGynecology	1999	56
Physical deterioration and adaptive recovery in physically inactive breast cancer patients during adjuvant chemotherapy: a randomised controlled trial Tom Møller, Christina Andersen, Christian Lillelund, Scientific Reports	2020	51

Page 1